Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in New Jersey: - Cooper Hospital University Medical Center — Camden, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- MD Anderson Cancer Center at Cooper-Voorhees — Voorhees Township, New Jersey
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in New Jersey: - Morristown Medical Center — Morristown, New Jersey
- Overlook Hospital — Summit, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in New Jersey: - Atlantic Health System Morristown Medical Center — Morristown, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in New Jersey: - Astera Cancer Care — East Brunswick, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in New Jersey: - Astera Cancer Care — East Brunswick, New Jersey
- Local Institution - 0363 — Ridgewood, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in New Jersey: - Morristown Medical Center — Morristown, New Jersey
Phase 3 Recruiting Industry
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dex…
Sponsor: Pfizer
NCT ID: NCT05020236
Sites in New Jersey: - MSK Basking Ridge — Basking Ridge, New Jersey
- MSK Monmouth — Middletown, New Jersey
- MSK Bergen — Montvale, New Jersey
Phase 2 Recruiting NIH
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in New Jersey: - Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period o…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06232044
Sites in New Jersey: - Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Sponsor: AstraZeneca
NCT ID: NCT05850234
Sites in New Jersey: - Research Site — Hackensack, New Jersey
Phase 2 Recruiting Industry
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…
Sponsor: Sanofi
NCT ID: NCT06356571
Sites in New Jersey: - Hackensack Meridian Health - Hackensack University Medical Center- Site Number : 8400021 — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in New Jersey: - Atlantic Health — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 2 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called r…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07266441
Sites in New Jersey: - Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Industry
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and ne…
Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT02343042
Sites in New Jersey: - Hackensack University Medical Center - John Theurer Cancer Center — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14)…
Sponsor: BeOne Medicines
NCT ID: NCT04973605
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively trea…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03761108
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 2 Recruiting Network
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be a…
Sponsor: Multiple Myeloma Research Consortium
NCT ID: NCT06171685
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem c…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05828511
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multipl…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06083922
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06976476
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area \[BSA\]-dosed melphalan) in people with multiple myeloma (MM) who are receiving a…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06679829
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their d…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07454382
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06066346
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey